All
The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.
Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.
ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer
Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.
Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs
Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.
CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer
Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.
Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC
Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.
Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer
Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.
Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract
A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
Bezuclastinib Plus Sutent May Be Safe and Effective in GIST
Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.
When Cancer Is Not the Only Thing Going On
My journey as a foster parent paralleled my cancer experience, both demanding resilience, support, and a redefinition of normal.
Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis
Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.
Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T
From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.
Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers
Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.
Opdivo Plus Chemo Shows 5-Year Efficacy in Gastric, GEJ and Esophageal Cancer
Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.
SHR-1701 Combo Reduces Chemo-Related Myelosuppression in Gastric/GEJ Cancer
SHR-1701 plus chemo suppressed chemo-associated myelosuppression in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Afinitor Plus Somatuline Prolongs Survival in GEP-NETs
Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
Matching Patient Needs with Oncologists’ Strengths in Cancer Care
Following a lung cancer diagnosis, I learned that it is important to ask oncologists thoughtful questions to know if they are the best doctor for my needs.
The FDA Accepts a BLA for RP1 Plus Opdivo in Advanced Melanoma
The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.
Driving Awareness, Action and Empowerment During Cervical Cancer Awareness Month
Dr. Ritu Salani discussed Cervical Cancer Awareness Month, highlighting what patients with this disease should be aware of as well as prevention tactics.
Feeding Souls: A Cancer Journey Through the Lens of Food
I've learned that cooking for friends during their cancer journey is a way to express love and support, even if it doesn't cure them.
With Cancer in Remission, What is the New Normal for Princess Kate?
CURE® spoke with experts about what life is like for patients with cancer when their disease is in remission.
Rising from Ashes: Rediscovering Myself After Multiple Myeloma
I rediscovered myself through community, writing, music and cooking after my journey with multiple myeloma.
Understanding the Concept of MRD for Patients With Cancer
Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.
An Expert Expands on What Drives ‘Exceptional’ Responses to RCC Treatment
Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.
Understanding the Challenges of CAR T-Cell Therapy Treatment in R/R NHL
Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.
The Power of Unity: Why the Lung Cancer Genetics Study Matters
The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer
Glucarpidase May Improve Renal Outcomes in Lymphoma, Leukemia
Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.
My New Year’s Resolution After A Testicular Cancer Diagnosis
My New Year's resolutions have evolved from seeking external goals to embracing personal growth and appreciating each day.
Improving Efficacy, Minimizing Toxicity in Chemotherapy For Breast Cancer
An expert spoke with CURE about providers’ “two-fold goal” when using chemotherapy to treat patients with breast cancer.
